Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
BJU Int
    December 2025
  1. RUSH HL, Merrick S, Marshall J, Deighan J, et al
    Preferences between three options for androgen deprivation therapy: a focus group study.
    BJU Int. 2025;136:1037-1047.
    >> Share

    November 2025
  2. VAN DEN EYNDE L, Ost P, Lumen N
    Authors' reply to: comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
    BJU Int. 2025 Nov 27. doi: 10.1111/bju.70098.
    >> Share

  3. ZHAO K, Zhou Z, Dong Z
    Comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
    BJU Int. 2025 Nov 27. doi: 10.1111/bju.70097.
    >> Share

  4. LU G, Wang J, Zheng W, Yu H, et al
    Immune checkpoint inhibitor nivolumab induces durable response in microsatellite instability-high and DNA damage repair-deficient metastatic castration-resistant prostate cancer.
    BJU Int. 2025 Nov 14. doi: 10.1111/bju.70084.
    >> Share

  5. SOON YY, Marschner IC, Schou IM, Sweeney CJ, et al
    Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
    BJU Int. 2025 Nov 5. doi: 10.1111/bju.70065.
    >> Share

  6. DAS A, Bigarella M, Brackman K, Allen GO, et al
    Prostate zonal impact of 5alpha-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
    BJU Int. 2025 Nov 5. doi: 10.1111/bju.70067.
    >> Share

  7. BUSHATI Y, Guo AA, Muston BT, Bushati A, et al
    Focal laser ablation in prostate cancer: a systematic review and meta-analysis.
    BJU Int. 2025 Nov 4. doi: 10.1111/bju.70064.
    >> Share

  8. HANDA N, Shore ND, Cooperberg MR, Davicioni E, et al
    Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
    BJU Int. 2025;136:920-929.
    >> Share

  9. UEKI H, Uemura M, Chinzei K, Takahashi K, et al
    Developing an artificial intelligence model for phase recognition in robot-assisted radical prostatectomy.
    BJU Int. 2025;136:891-901.
    >> Share

    October 2025
  10. MA L, Lu R, Dong Z
    Comment on 'Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity'.
    BJU Int. 2025 Oct 23. doi: 10.1111/bju.70032.
    >> Share

  11. CANNOLETTA D, Stabile A, Quarta L, Barletta F, et al
    Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history.
    BJU Int. 2025 Oct 13. doi: 10.1111/bju.70027.
    >> Share

  12. SIGHINOLFI MC, Pallotta G, Assumma S, Panio E, et al
    A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease.
    BJU Int. 2025 Oct 10. doi: 10.1111/bju.70019.
    >> Share

  13. MARQUIS A, Schwartz MJ, Armache A, Solosky K, et al
    Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.
    BJU Int. 2025 Oct 9. doi: 10.1111/bju.70014.
    >> Share

  14. GILL S, Chen R, Lamb BW, Moore CM, et al
    Interventions for patients with prostate cancer on active surveillance: a narrative review.
    BJU Int. 2025 Oct 6. doi: 10.1111/bju.70005.
    >> Share

  15. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
    Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'.
    BJU Int. 2025 Oct 3. doi: 10.1111/bju.70024.
    >> Share

  16. HALL R, Ball R, Bancroft E, Eeles R, et al
    Systematic review of PSA reference intervals in the gender diverse population with prostates.
    BJU Int. 2025;136:568-577.
    >> Share

  17. VISSCHER J, Bonevski B, O'Callaghan M
    The association of smoking with urinary and sexual function recovery following radical prostatectomy.
    BJU Int. 2025;136:647-656.
    >> Share

  18. LEWICKI P, Ginsburg K, Mmonu N, Labardee C, et al
    What is lost in an average? Identifying distinct post-radical prostatectomy functional recovery profiles.
    BJU Int. 2025;136:633-639.
    >> Share

  19. HUANG S, Chen DC, Qu L, Papa N, et al
    A meta-analysis of Retzius-sparing and hood-technique robot-assisted radical prostatectomy.
    BJU Int. 2025;136 Suppl 2:S18-S27.
    >> Share

    September 2025
  20. BONADDIO J, Carll J, Eapen R, Sathianathen N, et al
    The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.
    BJU Int. 2025 Sep 30. doi: 10.1111/bju.70015.
    >> Share

  21. VAN DEN EYNDE L, Ost P, Verla W, Everaerts W, et al
    Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70006.
    >> Share

  22. ZAURITO P, Westerberg M, Garmo H, Gedeborg R, et al
    Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score.
    BJU Int. 2025 Sep 12. doi: 10.1111/bju.16927.
    >> Share

  23. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
    >> Share

  24. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Reply to 'Comment on Bertini et al.: area deprivation and PSA screening disparities' and 'Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
    >> Share

  25. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    >> Share

  26. VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al
    Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
    BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
    >> Share

  27. COLLINS KK, Virdee PS, Roberts N, Oke JL, et al
    Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.
    BJU Int. 2025;136:372-384.
    >> Share

  28. BERRENS AC, Buckle T, van Oosterom MN, Slof LJ, et al
    Renal clearance of fluorescent agents can compromise image-guided surgery along the urinary tract.
    BJU Int. 2025;136:515-522.
    >> Share

  29. LENI R, Tin AL, Liso N, Carlsson SV, et al
    Magnetic resonance imaging for long-term active surveillance biopsy decision-making.
    BJU Int. 2025;136:500-506.
    >> Share

  30. LEPOR H, Persily J, Parry S, Rapoport E, et al
    Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
    BJU Int. 2025;136:447-451.
    >> Share

  31. KHAN N, Prezzi D, Raison N, Shepherd A, et al
    Impact of three-dimensional prostate models during robot-assisted radical prostatectomy on surgical margins and functional outcomes.
    BJU Int. 2025;136:420-428.
    >> Share

    August 2025
  32. SATAPATHY P, Mehta R, Sah R
    Comment on 'Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management'.
    BJU Int. 2025 Aug 28. doi: 10.1111/bju.16914.
    >> Share

  33. ZHOU SR, Zhang L, Choi MH, Vesal S, et al
    ProMUS-NET: Artificial intelligence detects more prostate cancer than urologists on micro-ultrasonography.
    BJU Int. 2025 Aug 27. doi: 10.1111/bju.16892.
    >> Share

  34. ITO K, Mori K, Kumar R, Sabnis RB, et al
    Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia.
    BJU Int. 2025 Aug 24. doi: 10.1111/bju.16900.
    >> Share

  35. CHIAM K, Bang A, Nair-Shalliker V, Caruana M, et al
    Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16896.
    >> Share

  36. CHONG B, Chen K
    Reply to 'A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer' by Su et al.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16898.
    >> Share

  37. SU PJ, Shao IH, Lin YH
    A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16897.
    >> Share

  38. FLETCHER SA, Macura KJ, Pavlovich CP
    Author response to comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 17. doi: 10.1111/bju.16869.
    >> Share

  39. OLIVIER J, Vertosick E, Delobel L, Bommelaere T, et al
    Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16884.
    >> Share

  40. SANAPALA K, Mehta R, Sah R
    Comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 2. doi: 10.1111/bju.16868.
    >> Share

  41. SANTUCCI J, Stapleton P, Perera M, Ischia J, et al
    Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies.
    BJU Int. 2025 Aug 1. doi: 10.1111/bju.16870.
    >> Share

    July 2025
  42. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency.
    BJU Int. 2025 Jul 30. doi: 10.1111/bju.16875.
    >> Share

  43. CARLL J, Shi W, Perera M, Lawrentschuk N, et al
    Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16872.
    >> Share

  44. GOTO Y, Urabe F, Ogihara Y, Nakata M, et al
    Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management.
    BJU Int. 2025 Jul 19. doi: 10.1111/bju.16860.
    >> Share

  45. ZHANG K, Teoh J, Laguna P, de la Rosette J, et al
    Response to Veldi et al.: 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy' - a critical appraisal.
    BJU Int. 2025 Jul 15. doi: 10.1111/bju.16840.
    >> Share


  46. Prostate cancer: detection, treatment and follow-up.
    BJU Int. 2025;136:2-3.
    >> Share

  47. EID N, Lepor H
    Incidence, surveillance and natural history of high-grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy.
    BJU Int. 2025;136:159-164.
    >> Share

  48. HAGMAN A, Lantz A, Grannas D, Carlsson S, et al
    Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups.
    BJU Int. 2025;136:135-142.
    >> Share

  49. ROBERTS MJ, Arora S, Yao HH, Hogan D, et al
    Transperineal prostate biopsy under local vs general anaesthesia: a cost-effectiveness analysis.
    BJU Int. 2025;136:128-134.
    >> Share

  50. KHATTAK A, Ruta D, Patkar V, Popert R, et al
    Artificial intelligence-driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary NHS centre in the UK.
    BJU Int. 2025 Jul 1. doi: 10.1111/bju.16845.
    >> Share

    June 2025
  51. SCHIEDA N, Morash C, Lavallee LT, Flood TA, et al
    Prostate cancer detection by MRI-ultrasonography fusion transperineal vs transrectal biopsy: a randomised control trial.
    BJU Int. 2025 Jun 27. doi: 10.1111/bju.16831.
    >> Share

  52. VELDI VDK, Mehta R, Sah R
    Comment on 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy'.
    BJU Int. 2025 Jun 26. doi: 10.1111/bju.16841.
    >> Share

  53. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    >> Share

  54. TOH EA, White J, Clarke J, Hider P, et al
    Variation in prostate cancer assessment and management between Maori and non-Maori in New Zealand.
    BJU Int. 2025 Jun 13. doi: 10.1111/bju.16805.
    >> Share

  55. FLETCHER SA, Alshak MN, Lee S, Singla N, et al
    Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions.
    BJU Int. 2025 Jun 12. doi: 10.1111/bju.16816.
    >> Share

    May 2025
  56. LIU J, Woon DTS, Perera M, Lawrentschuk N, et al
    Active surveillance in prostate cancer: when to exit and what are the options?
    BJU Int. 2025 May 19. doi: 10.1111/bju.16744.
    >> Share

  57. ALSHAK MN, Higgins MI, Grutman AJ, Campbell J, et al
    Prostate cancer active surveillance in solid organ transplant: a matched study and literature review.
    BJU Int. 2025 May 14. doi: 10.1111/bju.16777.
    >> Share


  58. Recent key papers in prostate cancer.
    BJU Int. 2025;135:710-711.
    >> Share

  59. CHEN DC, Huang S, Papa N, Siva S, et al
    Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
    BJU Int. 2025;135:720-732.
    >> Share

  60. GROSSMANN NC, Aschwanden FJ, Cornelius J, Malkmus C, et al
    Impact of patient positioning during surgery on neuropathies after robot-assisted laparoscopic radical prostatectomy: a randomised controlled trial.
    BJU Int. 2025;135:802-809.
    >> Share

    April 2025
  61. SILAGY AW, Woon DTS, Kostos L, Bernardino R, et al
    Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
    BJU Int. 2025 Apr 25. doi: 10.1111/bju.16751.
    >> Share

  62. PYRGIDIS N, Chaloupka M, Ebner B, Volz Y, et al
    Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study.
    BJU Int. 2025 Apr 19. doi: 10.1111/bju.16746.
    >> Share

  63. HO P, Kaufmann B, Gorin MA
    Case of the Month from the Icahn School of Medicine at Mount Sinai, New York, NY: MRI/TRUS fusion-guided biopsy of a local prostate cancer recurrence using the bladder for image registration.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16698.
    >> Share

  64. SUSHENTSEV N, Comune R, Sinci KA, Blyuss O, et al
    A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16743.
    >> Share

  65. DE VOS II, Marenghi C, Badenchini F, Boeve ER, et al
    Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16727.
    >> Share

  66. OLSSON K, Delilovic S, Enelius MB, Hagglund A, et al
    Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study.
    BJU Int. 2025 Apr 6. doi: 10.1111/bju.16735.
    >> Share

  67. ZHANG K, Teoh J, Laguna P, Dominguez-Escrig J, et al
    The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy.
    BJU Int. 2025 Apr 4. doi: 10.1111/bju.16720.
    >> Share


  68. Correction to "Prostate cancer in transgender women: what does a urologist need to know?".
    BJU Int. 2025 Apr 3. doi: 10.1111/bju.16723.
    >> Share

  69. NOLSOE AB, Logager V, Boesen L, Ostergren PB, et al
    Association of bi-parametric MRI measures with continence after robot-assisted radical prostatectomy.
    BJU Int. 2025;135:603-610.
    >> Share

  70. ENGESSER C, Brantner P, Gahl B, Walter M, et al
    3D-printed model for resection of positive surgical margins in robot-assisted prostatectomy.
    BJU Int. 2025;135:657-667.
    >> Share

    March 2025
  71. KAM J, Chalasani V, Goolam AS, Bergersen P, et al
    Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16654.
    >> Share

  72. MAYOR N, Light A, Silvanto A, Cullen E, et al
    Fluorescence confocal microscopy for margin assessment in prostatectomy: IP8-FLUORESCE study protocol.
    BJU Int. 2025;135:502-509.
    >> Share

  73. BOESEN L, Norgaard N, Bisbjerg R, Logager V, et al
    Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy.
    BJU Int. 2025;135:465-472.
    >> Share

    February 2025
  74. ORTNER G, Falkenbach F, Kachanov M, Inderhees T, et al
    External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16687.
    >> Share

  75. XIE S, Liu J, Shen B, Xu H, et al
    Salvage low-dose vs high-dose brachytherapy for radio-recurrent prostate cancer.
    BJU Int. 2025 Feb 9. doi: 10.1111/bju.16639.
    >> Share

  76. RODRIGUEZ-SANCHEZ L, Cathelineau X, de Reijke TM, Stricker P, et al
    Refining partial gland ablation for localised prostate cancer: the FALCON project.
    BJU Int. 2025 Feb 4. doi: 10.1111/bju.16669.
    >> Share


  77. Outcomes of prostate cancer treatments.
    BJU Int. 2025;135:184-185.
    >> Share

  78. SOPUTRO NA, Ramos-Carpinteyro R, Chavali JS, Pedraza AM, et al
    Predictors for selection of outpatient single-port robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2025;135:249-259.
    >> Share

    January 2025
  79. GNANAPRAGASAM VJ, Keates A, Lophatananon A, Thankapannair V, et al
    The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.
    BJU Int. 2025 Jan 29. doi: 10.1111/bju.16666.
    >> Share

  80. PYLVALAINEN J, Talala K, Raitanen J, Rannikko A, et al
    Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result.
    BJU Int. 2025 Jan 22. doi: 10.1111/bju.16641.
    >> Share

  81. CHONG B, Saad M, Chong TW, Thng J, et al
    Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
    BJU Int. 2025 Jan 2. doi: 10.1111/bju.16632.
    >> Share

  82. CHIU PK, Liu AQ, Lau SY, Teoh JY, et al
    A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
    BJU Int. 2025;135:71-77.
    >> Share

    December 2024
  83. OKHAWERE KE, Razdan S, Beksac AT, Saini I, et al
    Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet((R))) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16617.
    >> Share

  84. GELIKMAN DG, Azar WS, Yilmaz EC, Lin Y, et al
    A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16616.
    >> Share

  85. NOURMOHAMMADI ABADCHI S, Salles DC, Flannery C, Sama V, et al
    Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
    BJU Int. 2024;134:939-944.
    >> Share

  86. MERSEBURGER AS, Agarwal N, Bjartell A, Uemura H, et al
    Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
    BJU Int. 2024;134:982-991.
    >> Share

  87. CRISAFI D, Wong BNX, Bolton D, Ischia J, et al
    Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
    BJU Int. 2024;134 Suppl 2:12-13.
    >> Share

  88. ROBERTS MJ, Papa N, Veerman H, de Bie K, et al
    Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
    BJU Int. 2024;134 Suppl 2.
    >> Share

    November 2024
  89. MARTIN A, Mahmoud AM, Britton CJ, Fadel A, et al
    In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
    BJU Int. 2024 Nov 30. doi: 10.1111/bju.16598.
    >> Share

  90. SII S, Papa N, Yiu TW, Tempo J, et al
    Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.
    BJU Int. 2024 Nov 28. doi: 10.1111/bju.16597.
    >> Share

  91. THIMANSSON E, Axen E, Jaderling F, Styrke J, et al
    A novel approach to integrated prostate cancer diagnostics: insights from MRI, prostate biopsy, and pathology reports in a pilot study.
    BJU Int. 2024 Nov 12. doi: 10.1111/bju.16582.
    >> Share

  92. RAVAL AD, Chen S, Littleton N, Constantinovici N, et al
    Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
    BJU Int. 2024 Nov 12. doi: 10.1111/bju.16577.
    >> Share

  93. RANS K, Goffin K, Joniau S, Daugaard G, et al
    The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
    BJU Int. 2024 Nov 6. doi: 10.1111/bju.16574.
    >> Share

  94. TAKAHASHI T
    The first step in shared decision-making for prostate cancer screening.
    BJU Int. 2024 Nov 6. doi: 10.1111/bju.16580.
    >> Share

  95. LIU J, Cundy TP, Woon DTS, Desai N, et al
    A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer.
    BJU Int. 2024;134:714-722.
    >> Share

  96. MUSI G, Mistretta FA, Ivanova M, de Cobelli O, et al
    Evaluation of margins during radical prostatectomy: confocal microscopy vs frozen section analysis.
    BJU Int. 2024;134:773-780.
    >> Share

    October 2024
  97. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    >> Share

  98. LI T, Graham PL, Cao B, Nalavenkata S, et al
    Accuracy of MRI in detecting seminal vesicle invasion in prostate cancer: a systematic review and meta-analysis.
    BJU Int. 2024 Oct 22. doi: 10.1111/bju.16547.
    >> Share

  99. ANG ZY, Kong YL, Md Nesran ZN, Lee SWH, et al
    Efficacy of decision aid delivery modes in prostate cancer screening: umbrella review and network meta-analysis.
    BJU Int. 2024 Oct 14. doi: 10.1111/bju.16545.
    >> Share

  100. LAZAROVICH A, Kristof TW, Steadman S, Dahmen AS, et al
    Prostate cancer and solid organ transplantation: patient management and outcomes.
    BJU Int. 2024 Oct 9. doi: 10.1111/bju.16558.
    >> Share

  101. GONZALEZ-SAN SEGUNDO C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, et al
    A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
    BJU Int. 2024;134:568-577.
    >> Share

  102. KINNEAR N, Fonseca PC, Ogbechie C, Adam S, et al
    Impact of frozen section on long-term outcomes in robot-assisted laparoscopic prostatectomy.
    BJU Int. 2024;134:608-614.
    >> Share

  103. TAYA M, Behr SC, Westphalen AC
    Perspectives on technology: Prostate Imaging-Reporting and Data System (PI-RADS) interobserver variability.
    BJU Int. 2024;134:510-518.
    >> Share

  104. SAHNI DS, Morrison J, Leung HY
    Grid-based cognitive diagnostic prostatic biopsy without transrectal ultrasonography.
    BJU Int. 2024;134:659-663.
    >> Share

    September 2024
  105. FANG AM, Gregg JR, Pettaway C, Ma J, et al
    Whole-body MRI for staging prostate cancer: a narrative review.
    BJU Int. 2024 Sep 22. doi: 10.1111/bju.16514.
    >> Share


  106. Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs.
    BJU Int. 2024;134:321-322.
    >> Share

  107. REIJNDERS-BOERBOOM GTJA, Jacobs LMC, Helder LS, Panhuizen IF, et al
    Recovery and immune function after low pressure pneumoperitoneum during robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:416-425.
    >> Share

  108. TOUZANI A, D'Agate D, Kesch C, Calleris G, et al
    One-year outcomes of same-day-discharge robot-assisted radical prostatectomy.
    BJU Int. 2024;134:380-382.
    >> Share

  109. OUCHI M, Kitta T, Chiba H, Higuchi M, et al
    Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:398-406.
    >> Share

  110. BATES AS, Sharma AD, Camilleri P, Browning L, et al
    'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.
    BJU Int. 2024;134:377-379.
    >> Share

    August 2024
  111. TAKAHASHI T
    Observational study on screen-detected prostate cancer: case series of empirical clinical practice.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16525.
    >> Share

  112. ONG WL, Krishnaprasad K, Bensley J, Steeper M, et al
    Population-based prostate cancer outcomes registries - what have we learned and where are we heading?
    BJU Int. 2024 Aug 19. doi: 10.1111/bju.16487.
    >> Share

  113. GEBOERS B, Scheltema MJ, Jung J, Bakker J, et al
    Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
    BJU Int. 2024 Aug 5. doi: 10.1111/bju.16496.
    >> Share

  114. JACEWICZ M, Rud E, Lauritzen P, Baco E, et al
    Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia.
    BJU Int. 2024;134:300-306.
    >> Share

  115. FANKHAUSER CD, Malkmus C, Aschwanden F, Baumeister P, et al
    'Igloo' technique for robot-assisted radical prostatectomy - maximum nerve sparing for early recovery of continence and sexual function.
    BJU Int. 2024;134:307-311.
    >> Share

  116. ABUELNAGA M, Gendy R, Yao M, Phelan C, et al
    Impact of definitions on continence outcomes in a series of 1000 robot-assisted radical prostatectomies, time for an internationally agreed definition?
    BJU Int. 2024;134:197-200.
    >> Share

  117. NG KL, Giona S, Barber N
    Feasibility of Aquablation prostate surgery performed as day cases.
    BJU Int. 2024;134:185-186.
    >> Share

    July 2024
  118. BANCROFT EK
    Response to BJU-2024-0780: RE: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    BJU Int. 2024 Jul 26. doi: 10.1111/bju.16490.
    >> Share

  119. DAUNGSUPAWONG H, Wiwanitkit V
    RE: 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers'.
    BJU Int. 2024 Jul 26. doi: 10.1111/bju.16489.
    >> Share

  120. YANG J, Xiong X, Wei Q, Yang L, et al
    Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer.
    BJU Int. 2024 Jul 17. doi: 10.1111/bju.16467.
    >> Share

  121. MAURER J, Ambrosini F, Chen Y, Schroeder S, et al
    Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply.
    BJU Int. 2024 Jul 16. doi: 10.1111/bju.16468.
    >> Share

  122. SCHMIDT B, Soerensen SJC, Bhambhvani HP, Fan RE, et al
    External validation of an artificial intelligence model for Gleason grading of prostate cancer on prostatectomy specimens.
    BJU Int. 2024 Jul 11. doi: 10.1111/bju.16464.
    >> Share

  123. WENZEL M, Hoeh B, Koll F, Humke C, et al
    Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
    BJU Int. 2024 Jul 10. doi: 10.1111/bju.16462.
    >> Share

  124. ARVIDSSON I, Svanemur E, Marginean F, Simoulis A, et al
    Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
    BJU Int. 2024 Jul 4. doi: 10.1111/bju.16456.
    >> Share


  125. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int. 2024;134:4-5.
    >> Share

  126. JUSSILA I, Ahtiainen JP, Laakkonen EK, Siltari A, et al
    Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol.
    BJU Int. 2024;134:110-118.
    >> Share

  127. SOPUTRO NA, Chavali JS, Ferguson EL, Ramos-Carpinteyro R, et al
    Complications of single-port robot-assisted radical prostatectomy: multi-institutional analysis from the Single-Port Advanced Research Consortium (SPARC).
    BJU Int. 2024;134:54-62.
    >> Share

  128. MORETTI TBC, Magna LA, Reis LO
    Continence criteria of 193 618 patients after open, laparoscopic, and robot-assisted radical prostatectomy.
    BJU Int. 2024;134:13-21.
    >> Share

    June 2024
  129. KATO T, Matsumoto R, Yokomizo A, Tohi Y, et al
    Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
    BJU Int. 2024 Jun 17. doi: 10.1111/bju.16436.
    >> Share

  130. BANCROFT EK, Page EC, Brook MN, Pope J, et al
    The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    BJU Int. 2024 Jun 5. doi: 10.1111/bju.16432.
    >> Share

  131. HAHN AW, Manyam GC, Chapin BF, Zhang M, et al
    A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
    BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414.
    >> Share


  132. Prostate cancer: To screen, or not to screen? That is the question.
    BJU Int. 2024;133:635-637.
    >> Share

  133. FRANCO A, Ditonno F, Manfredi C, Licari LC, et al
    Robot-assisted single-port transvesical enucleation of the prostate: step-by-step technique and early single-centre experience.
    BJU Int. 2024;133:778-782.
    >> Share

  134. NOLSOE AB, Ostergren PB, Jakobsen H, Jensen CFS, et al
    Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial.
    BJU Int. 2024;133:742-751.
    >> Share

  135. MAURER J, Friedemann T, Chen Y, Ambrosini F, et al
    A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy.
    BJU Int. 2024;133:725-732.
    >> Share

  136. LENFANT L, Beitone C, Troccaz J, Roupret M, et al
    Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation.
    BJU Int. 2024;133:709-716.
    >> Share

  137. ALMEIDA-MAGANA R, Au M, Al-Hammouri T, Dinneen K, et al
    Improving fluorescence confocal microscopy for margin assessment during robot-assisted radical prostatectomy: The LaserSAFE technique.
    BJU Int. 2024;133:677-679.
    >> Share

  138. MAC CURTAIN BM, Sugrue DD, Qian W, O'Callaghan M, et al
    Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis.
    BJU Int. 2024;133:646-655.
    >> Share

    May 2024
  139. GALIETTA E, Strolin S, Lodi-Rizzini E, Castellucci P, et al
    Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
    BJU Int. 2024 May 22. doi: 10.1111/bju.16399.
    >> Share

  140. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
    Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
    BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
    >> Share

  141. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
    A review of vitamin use for the prevention or treatment of prostate cancer.
    BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
    >> Share

  142. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
    Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
    BJU Int. 2024 May 9. doi: 10.1111/bju.16394.
    >> Share

  143. GRAJALES V, Martini A, Shore ND
    Complications of immuno-oncology care: what urologist should know.
    BJU Int. 2024;133:524-531.
    >> Share

  144. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
    Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    BJU Int. 2024;133:548-554.
    >> Share

    April 2024
  145. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
    Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
    BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
    >> Share

  146. STATTIN P, Fleming S, Lin X, Lefresne F, et al
    Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
    >> Share

  147. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
    The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
    BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
    >> Share

  148. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
    Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
    BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
    >> Share

  149. VICKERS A
    Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
    BJU Int. 2024;133:354-355.
    >> Share

  150. MCNICHOLAS DP, Parr NJ
    Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
    BJU Int. 2024;133:487-490.
    >> Share

  151. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
    Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
    BJU Int. 2024;133:432-441.
    >> Share

  152. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
    Prostate tumour visualisation with PET: is image fusion with MRI the answer?
    BJU Int. 2024;133 Suppl 4:4-6.
    >> Share

    March 2024
  153. ALBERTSEN PC
    Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
    BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
    >> Share

  154. TAKAHASHI T
    Endpoint and control group in prostate cancer screening research: public health basics.
    BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
    >> Share

  155. PAK JS, Huang R, Huang WC, Lepor H, et al
    Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
    BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
    >> Share

  156. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
    >> Share

  157. HAMDY FC, Albertsen PC, Donovan JL
    Screening and active surveillance in prostate cancer: the dilemma continues.
    BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
    >> Share

  158. HUBER J, Karschuck P, Valdix J, Thomas C, et al
    Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
    >> Share

  159. TAKAHASHI T
    Active surveillance in all cases of screen-detected prostate cancer.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
    >> Share

  160. ROKAN N, Reddy D, Dudderidge T
    Focal therapy for prostate cancer - when to refer?
    BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
    >> Share

  161. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
    Evolution of European prostate cancer screening protocols and summary of ongoing trials.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
    >> Share

  162. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
    Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
    >> Share

  163. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
    Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
    BJU Int. 2024;133:324-331.
    >> Share

    February 2024
  164. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
    Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
    >> Share

  165. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
    During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
    BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
    >> Share

  166. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
    (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
    BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
    >> Share

  167. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
    Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
    BJU Int. 2024;133:197-205.
    >> Share

  168. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
    International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
    BJU Int. 2024;133:179-187.
    >> Share

  169. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
    How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    BJU Int. 2024;133 Suppl 3:13-14.
    >> Share

  170. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
    The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    BJU Int. 2024;133 Suppl 3:39-47.
    >> Share

    January 2024
  171. SANCHEZ-SALAS R
    Candid choices: optimising patient selection in prostate cancer focal therapy.
    BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
    >> Share

  172. BESIROGLU H
    Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
    >> Share

  173. TALWAR R, Akinsola O, Penson DF
    What is cancer? A focus on Grade Group 1 prostate cancer.
    BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
    >> Share

  174. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
    Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
    BJU Int. 2024;133:104-111.
    >> Share

  175. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
    Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
    BJU Int. 2024;133:112-117.
    >> Share

    December 2023
  176. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
    LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
    >> Share

  177. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
    Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
    >> Share

    November 2023
  178. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
    AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
    BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
    >> Share

  179. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
    Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
    >> Share

  180. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
    BJU Int. 2023;132:568-574.
    >> Share

    October 2023
  181. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
    CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
    >> Share

  182. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
    Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
    BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
    >> Share

  183. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
    PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
    >> Share

  184. TISSOT S, Wynn J, Tran V, Farag M, et al
    Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
    BJU Int. 2023;132:411-419.
    >> Share

  185. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
    Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
    BJU Int. 2023;132:397-403.
    >> Share

    September 2023
  186. LEHNER F, Crippa A, Sigg S, Eberli D, et al
    Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
    >> Share

  187. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
    Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
    >> Share

  188. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
    Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
    BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
    >> Share

    June 2023
  189. BRANT A, Campi R, Carrion DM, Esperto F, et al
    Findings from an international survey of urology trainee experience with prostate biopsy.
    BJU Int. 2023;131:705-711.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016